Bettina Kulle Andreassen started at the Cancer Registry in 2015. She works on several projects in pharmacoepidemiology, which, using advanced statistical and epidemiological methods, explores the connection between drug use and cancer risk or cancer outcomes. Andreassen is a part of the action group for bladder and urothelial cancer in the Directorate of Health. She is also represented on the board of the Norwegian Cancer Registry and on the board of Janus Serumbank. Andreassen is a qualified statistician (PhD) from the University of Göttingen in Germany.
Bettina is working on several projects in pharmacoepidemiology, which through the use of advanced statistical and epidemiological methods, explores the relationship between drug use and cancer risk or cancer outcomes.
In a large «registry screening study», precisely all combinations of prescription drugs and cancers were analysed.
Bettina is also interested in urological cancers and supervises a postdoc and several PhD students in clinically oriented registry studies, focusing on the disease process (treatment, progression, survival) in bladder cancer patients and the use of newer drugs in cancer treatment for metastatic prostate cancer patients.
Bettina already has a lot of experience from genetic and epigenetic epidemiological studies.
Bettina is a member of the action plan group for bladder and urothelial cancer in the Norwegian Directorate of Health.
She is also represented on the Cancer Registry's board and on the board of the Janus Serum Bank.
Bettina holds a statistician (PhD) from the University of Göttingen in Germany.
Before joining the Cancer Registry of Norway in 2015, she worked as an associate professor at the University of Oslo.
Publications:
Støer NC, Botteri E, Thoresen GH, Karlstad Ø, Weiderpass E, Friis S, Pottegård A, Andreassen BK (2020)
Drug Use and Cancer Risk: A Drug-Wide Association Study (DWAS) in Norway
Cancer Epidemiol Biomarkers Prev (in press)
DOI 10.1158/1055-9965.EPI-20-1028, PubMed 33144282
Blindheim A, Fosså S, Babigumira R, Myklebust TÅ, Haug E, Arum CJ, Andreassen BK (2020)
T1 bladder cancer in Norway: treatment and survival
Scand J Urol, 54 (5), 370-375
DOI 10.1080/21681805.2020.1803401, PubMed 32783590
Andreassen BK, Støer NC, Martinsen JI, Ursin G, Weiderpass E, Thoresen GH, Debernard KB, Karlstad Ø, Pottegard A, Friis S (2019) Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study BMJ Open, 9 (4), e028504 DOI 10.1136/bmjopen-2018-028504, PubMed 30962244
LeBlanc M, Zuber V, Thompson WK, Andreassen OA, Schizophrenia and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, Frigessi A, Andreassen BK (2018) A correction for sample overlap in genome-wide association studies in a polygenic pleiotropy-informed framework BMC Genomics, 19 (1), 494 DOI 10.1186/s12864-018-4859-7, PubMed 29940862
Andreassen BK, Grimsrud TK, Haug ES (2018). Bladder cancer survival: Women better off in the long run. Eur J Cancer 95:52-58. DOI 10.1016/j.ejca.2018.03.001 PubMed 29635144
Media:
To millioner nordmenn med i ny registerstudie Dagensmedisin.no
Hvorfor holder alle kjeft om blærekreft? Aftenposten viten, 10. mai 2017
Derfor kan blærekreft være mer dødelig for kvinner Forskning.no
